Introduction
Fibroblast growth factor (FGF)-2 is the prototype member of a family of at least 23 structurally related heparin-binding growth factors. The FGF-2 signaling pathway has been shown to play determinant roles not only in development and physiopathological processes, but also in tumorigenesis and tumor progression (for review see Okada-Ban et al., 2000; Powers et al., 2000) for a wide variety of cells.
Four high-molecular-weight isoforms characterized by the presence of a nuclear localizing sequence could be alternatively synthesized either at an AUG codon (18 kDa) or CUG codon (22, 22.5 and 24 kDa) (Bugler et al., 1991; Arnaud et al., 1999) . Unlike other members of the FGF family, FGF-2 and also FGF-1 lack a conventional signal peptide sequence for secretion (Gospodarowicz, 1987; Miyamoto et al., 1993) . It is becoming increasingly clear, however, that FGF-2 can be released from living cells and then activates its own high-affinity receptors (reviewed in Bikfalvi et al., 1997) . A measure of 18 kDa FGF-2 is secreted, and induces cell proliferation and migration, whereas the nuclear HMW FGF-2(s) modulates cell proliferation. In some instances, antibodies directed against FGF-2 inhibit its biological function, thereby supporting an autocrine or paracrine mechanism of action (Sato and Rifkin, 1988; Plouet and Gospodarowicz, 1990; Mignatti et al., 1991) . The pioneer work of Rogelj (Rogelj et al., 1988) has pointed out that, if secreted, FGF-2 may have transforming potential.
Even endogenous or exogenous in vitro synthesis of FGF-2 stimulates the proliferation and migration of endothelial cells and, despite its well-known pharmacological activity in experimental or therapeutic angiogenesis, the actual role of FGF-2 in controlling angiogenesis remains controversial. It has been shown recently, for instance, that FGF-2 gene invalidation did not affect the development of retinal vessels nor attenuated pathological neovascularization (Ozaki et al., 1998) .
NBT-II cells are derived from a chemically induced rat bladder carcinoma. These cells do not express FGF-1, FGF-2 or FGFR-1, but do express the FGFR-2b receptor 2 spliced variant. As a result, these cells do not respond to exogenously added FGF-2, but respond to FGF-1. The constitutive expression of FGF-1 or FGF-2 by these carcinoma cells generates cells that secrete the corresponding growth factor and that in vivo allow the growth of highly vascularized tumors as well in autocrine or nonautocrine NBT-II-expressing cells (Jouanneau et al., 1997; Billottet et al., 2002) . However, a major difference in growth rate was observed: tumors developing NBT-II cells expressing FGF-2 grew like the control, whereas the growth rate of FGF-1-expressing cells was much faster (Jouanneau et al., 1997 (Jouanneau et al., , 1999 . Although constitutive expression of the high-affinity receptor FGFR-1 gave cells that have acquired the capacity to be activated by exogenous FGF-2, these cells induced tumors with growth properties similar to that of parental cells (Moscatelli, 1992) ; conversely, when they are engineered to constitutively express FGFR-1 and FGF-2, they behave like FGF-1-producing cells (Billottet et al., 2002) .
To revisit the relative contribution of FGF-1 and FGF-2 in NBT-II-derived tumor growth and angiogenesis, we focused on an alternate strategy to activate FGFR-1 and FGFR-2 directly. Since FGF-1 and FGF-2 are not circulating growth factors, we had to design selective circulating agonists of each FGF receptor. We therefore relied on the anti-idiotypic antibodies strategy (Jerne et al., 1982; Couraud and Strosberg, 1991) to activate FGF receptors. This strategy can be used to design probes mimicking a single epitope of a ligand, in particular a binding domain to its receptor. These antiidiotypic antibodies are called internal images and they not only display the same receptor-binding specificity, but also similar trafficking. Previously, we described the function of anti-idiotypic antibodies of VEGF binding to VEGFR-2, but not to VEGFR-1, and inducing cell proliferation, but not migration . In addition, VEGFR-2 dimerization achieved with this anti-idiotypic antibody is followed by its tyrosine phosphorylation and internalization. We demonstrate in this report that such specific immunoglobulins, termed AIdF-1 and AIdF-2, are, respectively, true internal images of FGF-1 and FGF-2, which mimicked the properties of FGF-1 on FGFR-2b and of FGF-2 on FGFR-1. This way of direct activation in tumor and angiogenesis is compared with that of NBT-II-rendered autocrine for FGF-1 and FGF-2 (Billottet et al., 2002) . FGFR1 is phosphorylated upon FGF-2 or AIdF-2 addition and it also promotes vascular endothelial cell proliferation. In vitro, treatment of NBT-II cells constitutively expressing FGFR1 by such anti-idiotype antibodies mimicking FGF-2 led to a decrease in their proliferation through PI3 kinase (PI3-K) and MAP kinase activation. In vivo, although AIdF-2 promoted corneal angiogenesis, its systemic injection led to a reduction in the tumor volume.
Results
Binding of AIdF-1 and AIdF-2 to FGFR-2b and FGFR-1
Despite their strong sequence homology and their ability to bind to the same FGF tyrosine kinase receptors, FGF-1 and FGF-2 differ in their binding affinities to FGFR-1 and FGFR-2. In order to design circulating agonists of FGFR-1 and FGFR-2 mimicking the properties of FGF-1 and FGF-2, we relied on the antiidiotypic antibodies strategy. Previously, we produced anti-FGF-1 and anti-FGF-2 antibodies, which did not crossreact with each other (Plouet and Gospodarowicz, 1990) . We then used these antibodies as antigens to immunize rabbits. We purified anti-idiotypic IgG and studied their capacity to mimic FGF-1 or FGF-2 signaling. In a first set of experiments, we compared their ability to compete with the binding of iodinated FGF-2 to pgsA-745 CHO cells expressing either FGFR-1 2 Ig loops (binding FGF-1 and FGF-2 with the same affinity) or FGFR-1 3 Ig loops (binding FGF-1 with an affinity 100-fold lower than FGF-2) (Basilico and Moscatelli, 1992; Moscatelli, 1992) . Accordingly, antiidiotypic IgG of FGF-1 (AIdF-1) and FGF-2 (AIdF-2) inhibited the binding of iodinated FGF-2 to each cell line, with IC 50 's of 0.25 and 1.9 nM for FGFR-1 2 Ig loops and 0.4 and 3.2 nM for FGFR-1 3 Ig loops, respectively (Figure 1a and b). AIdF-1 inhibited only FGF-2 binding to FGFR-1 2 Ig loops-transfected cells (Figure 1a ). Control PI-IgG could not compete with iodinated FGF-2 binding with any of the transfected cells (data not shown). Therefore, AidF-1 and AIdF-2 exhibit the same binding properties to FGFR-1 as the genuine ligands.
Biological activity of AIdF-1 and AIdF-2
As expected from an internal image, an anti-idiotypic antibody for a receptor ligand should mimic the natural ligand and therefore activate and phosphorylate the receptor. Indeed, the anti-idiotype antibodies AIdF-1 and AIdF-2, like FGF-1 and FGF-2, but not control PIIgG, induced tyrosine phosphorylation of FGFR-1 on ACE cells (Figure 2a) . Accordingly, AIdF-2 as well as AIdF-1 induced a dose-dependent mitogenic response in ACE-stimulated cells in the same range of FGF-2 (ED 50 of 0.6 and 0.9 nM, respectively, as compared to 0.1 nM for FGF-2, Figure 2b ). The mitogenic activity of FGF-2 and AIdF-2 was totally abolished by anti-FGF-2-neutralizing IgG, but not affected by anti-FGF-1 IgG (Figure 2c) . Similarly, the mitogenic activity of FGF-1 and AIdF-1 was totally abolished by anti-FGF-1-neutralizing IgG, but not by specific anti-FGF-2 antibodies (Figure 2c ). Neither PI-IgG nor polyclonal anti-VEGF IgG inhibited the mitogenic effect of Ald-Fl or AId-F2 (data not shown). These results emphasize the anti-idiotypic properties of both AIdF-1 and AIdF-2, and demonstrate that they were true internal images of the binding domains to the tyrosine kinase receptors of FGF-1 and FGF-2. AIdF-1 like FGF-1 induced a strong scattering effect of both NBT-II cells (not shown) and of NBT-II-FGFR1 cells (Figure 3c ). However, they do not modulate the proliferation of native NBT-II cells in low serum (Figure 3a) , thus demonstrating that FGFR2b was not involved in cell proliferation. As expected, AIdF-2 as well as FGF-2 did not alter the morphology nor the proliferation of parental NBT-II cells (data not shown). Conversely, FGF-2 and AIdF-2 significantly inhibited the proliferation of NBT-II/ FGFR1 cells cultured in low serum, as well as FGF-1, whereas AIdF-1 appeared devoid of such biological activity (Figure 3b ), thus suggesting that FGFR-1 signaling was involved in inhibiting proliferation. In addition, AldF-1, like FGF-1, FGF-2 and AIdF-2, induced cell scattering of NBT-II/FGFR1 cells.
Signal transduction
We checked whether the agonistic effect of AldF exerted on NBT-II transfected or not with FGFR-1 could mimic the signal transduction of FGF-1 and FGF-2. FGF-1 and Ald-Fl induced a similar activation (5.7 and 4.3 times above the control, respectively) of MAP kinase (Figure 4a ). ERK activation in response to FGF-1, AldFl or FGF-2 was maximal from 10 min onwards, whereas AIdF-2 remained ineffective for ERK activation up to 30 min. However, a longer exposure of 120 min induced ERK stimulation (Figure 4b ) at a level which remained lower than that induced by FGF-2 (5.8 times higher than the control at 10 min sustained at a level of 2.8 times higher than the control at 120 min). In contrast, the time course for PI3-K activation (P-PI3K) on FGF-2 or AIdF-2 was similar (Figure 4c) , and similar levels of phosphorylated PI3-K were detected for both stimulators from 15 to 120 min of stimulation. To identify the signaling pathways involved in the cell proliferation, we used specific inhibitors for MEK1 (PD98059), ERK1 (AG126), p38 MAPK (SB203580) and PI3K (wortmannin and LY294002). Treatment of FGFR1-transfected NBT-II cells with 10 mM PD98059 led to a significant decrease of ERK activation induced Corneal angiogenesis induced by AIdF-1 and AIdF-2 FGF-1 and FGF-2 induced a similar corneal angiogenesis (angiogenesis scores of 2.1 and 2.3 as compared with 0.3 for the vehicle alone). Since AIdF-1 and AIdF-2 induced the tyrosine phosphorylation of FGFR-1 and the proliferation of ACE endothelial cells, we tested whether these compounds could exert angiogenic activity in this in vivo model. When AIdF-1 or AldF-2 were inserted in slow-releasing pellets, they elicited a lower angiogenic response in the cornea than FGF-1 or FGF-2. The average angiogenic scores were 2.3 and 1.7, as compared with 0.4 for PI-IgG ( Figure 6 ). All these four FGF receptor agonists elicited a significant score of angiogenesis as compared to PI-IgG (Po0.05).
AIdF-2 decreases the tumor volume of NBT-II/FGFR-1 cells grafted in nude mice
We then investigated the physiopathological functions of FGFR-1 and FGFR-2b receptors in models of tumor development. Nude mice, subcutaneously inoculated with either NBT-II or NBT-II-FGFR1 cells, received an intraperitoneal injection of AIdF-1, AIdF-2 or of PIIgG twice a week. As seen in Figure 7a , neither AIdF-1, AIdF-2 nor PI-IgG affected the development of NBT-II tumors. In contrast, when AIdF-2 was injected in nude mice bearing tumors developed from FGFR1-transfected NBT-II cells, a significant decrease in tumor volume was observed, whereas AIdF-1 had no effect on tumor proliferation.
The lack of effect of both AIdF-1 and AIdF-2 on NBT-II tumor development suggested that the angiogenic effect observed in the corneal pocket assay did not occur or was not mandatory in this tumor model. Tumor sections labeled with anti-Factor VIII antibody did not reveal any statistical difference between the six groups ( Table 1) . The mitotic index also remained unchanged after AIdF-1 treatment (Table 1) , but was lower in NBT-II/FGFR-1 tumors treated with AIdF-2 than in those treated with AIdF-1. However, H & E staining showed striking differences in AIdF-1-treated tumors ( Figure 7b ). The foci of cancer cells (50-100 cells) were regular in size in PI-IgG-or AIdF-2-treated animals, whereas in AIdF-1-treated animals the foci were less numerous and contained a lower number of cells, in accordance with the scattering effect observed in vitro. This morphology was highly reminiscent of that observed in aggressive bladder tumors in which metastasis occurrence is correlated to the migration ability and dedifferentiation of cells. The ratio of the tumor section surface occupied by cancer and stromal cells (C/S ratio) in the NBT-II or NBT-II/FGFR1 tumors was assessed by image analysis (Table 1) . As expected, PI-IgG and AIdF-2 led to the same ratio (0.8870.11 and 0.9370.11, respectively), whereas AIdF-1 significantly reduced the cancer/stroma ratio (0.3970.04) in NBT-II tumors. Constitutive expression of FGFR-1 in NBT-II cells did not alter the morphology nor the relative distribution of cancer and stromal cells (ratio of 1.0570.20) . Surprisingly, AIdF-1 treatment was ineffective and the C/S ratio scored at 1.0470.14. Animals treated with AIdF-2 have well-differentiated tumors with hundreds of tumor cells clustering (C/S ratio: 1.9270.31).
Discussion
The anti-idiotypic strategy was developed to obtain putative internal images of growth factors such as FGF-1 and FGF-2, and thus to generate circulating agonists specific for distinct FGF receptors. Therefore, the activation of FGF receptors through an extracellular pathway could be assessed directly and compared with that mediated through the release of endogenous FGFs.
In this report, we show that anti-idiotypic antibodies of FGF-1 and FGF-2 mimic their biological effects on endothelial and cancer cells for binding, signal transduction, cell scattering and proliferation of cultured cells, as well as reduction of the development of NBT-II tumors expressing FGFRl. The straightforward demonstration that a heparinbinding growth factor such as FGF-2 acts through activating a tyrosine kinase receptor and not by releasing other growth factors from the extracellular matrix raises several methodological points. The systemic delivery of growth factors might be impaired by their inability to reach their targets as a result of being sequestered in the extracellular matrix. We never observed any modification of the tumor volume by injecting FGF-2 systemically. We thus had to construct circulating agonists mimicking the binding domains of FGF-1 or FGF-2 to their receptors, and therefore relied 2 ), were rehydrated with 2 ml PBS containing 50 mg of bovine serum albumin supplemented or not with 4 pmol of FGF-1, FGF-2, AIdF-1, AIdF-2 or PI-IgG. These implants were inserted in the corneal stroma 2 mm away from the limbus in female New Zealand rabbits. Neovascularization was assessed on day 12 by direct examination with a slit lamp and scored according to a 4 grade scale. The score was the mean of the area neovascularized and s.e.m. for each condition performed in 7-10 animals per condition Direct activation of FGF receptors by soluble agonists B Malavaud et al on the anti-idiotypic strategy. Anti-idiotypic antibodies were raised by priming lymphocytes in the lymph nodes with neutralizing IgG against FGF-1 or FGF-2 and obtaining specific agonists for FGFR-2b or FGFR-l. The characterization of the distinct binding domains of FGF-1 or FGF-2 for each FGF receptor remains a difficult task. Most attempts consist in mutating the growth factor gene and measuring the residual and biological functions. Nevertheless, this strategy does not take into account that distinct binding domains for each receptor might be conformation-dependent rather than sequence-dependent, and that the mutation of the gene might also profoundly affect the structure and the posttranslational conformation of the protein. In contrast, the use of an anti-idiotypic strategy might circumvent these difficulties since conformational epitopes are more likely recognized by the immune system. In addition, the paradigm of 'idiotypic restriction' predicts that each animal immunized with a neutralizing antibody will elicit anti-idiotypic antibodies against a limited number of idiotopes and, therefore, the probability of obtaining a specific agonist of a single receptor among several would be high (Jerne et al., 1982; Couraud and Strosberg, 1991) .
Our screening methodology demonstrated that 20% of the rabbits immunized with anti-FGF-1-or FGF-2-neutralizing IgG produced anti-idiotypic antibodies that bound specifically to CHO cells transfected with FGFR-l 3 Ig loops or FGFR-l 2 Ig loops in the same fashion as their corresponding immunogen: AIdF-2 and FGF-2 could not bind to NBT-II cells which express FGFR2b, but could bind to FGFRltransfected NBT-II cells, whereas FGF-1 and AIdF-1 bound to both cells. Although the inhibition of FGF binding to cell surface receptors detected by the radioreceptor assay used in these experiments might be inhibited nonspecifically by basic peptides competing with FGF or HSPG binding to FGF and FGF receptors (Bikfalvi et al., 1997) , it is unlikely that the activity of AIdF-1 or AIdF-2 resulted from nonspecific interactions because (i) IgG purified from serum are not basic, (ii) putative anti-idiotypic antibodies mimicking the binding domains of FGF-1 or FGF-2 to HSPG were removed by chromatography on heparin sepharose, (iii) they behaved like agonists of FGF receptors in inducing tyrosine phosphorylation of FGFR-l and mitogenic effect on microvascular endothelial cells. Moreover, their mitogenic effects were inhibited by neutralizing IgG directed against the corresponding growth factor, but not by neutralizing IgG directed against the other one, thus demonstrating that each AId was a true internal image of the corresponding FGF. Ligandindependent receptor activation by antireceptor antibodies has been demonstrated for other receptor tyrosine kinases. For example, IgG directed against the nerve growth factor high-affinity receptor TrkA can promote neuron survival. It was shown in such cases that bivalent IgG are required for antibody-dependent activation of the epidermal growth factor receptor or TrkA, probably because they mimic ligand-induced dimerization (Clary et al., 1994) . Studies of signal transduction following their binding to the FGF receptors also showed that AIdF-1 and AIdF-2 mimicked the corresponding growth factor. For instance, extracellular activation of FGFRl induced PI3-K and MAP kinase phosphorylation when NBT-II/ FGFR-l was exposed to either FGF-1, FGF-2 or AIdF-1 or AIdF-2. However, the kinetics of AIdF-2 was slower than that of FGF-2, whereas that of FGF-1 and AIdF-1 were similar. Moreover, MAP kinase and PI3-K activation achieved with the growth factors or anti-idiotypic antibodies were inhibited by the specific PD 98059 and LY294002 inhibitors to a similar extent, thus showing that the signal transduction cascade does not require intracellular translocation of FGF-1 or FGF-2.
The study of carcinoma cell scattering showed that both FGFR-1 and FGFR-2b activation by the antiidiotype antibodies resulted in epithelio-mesenchymal transition. In contrast, the activation of FGFR-2b by either FGF-1 or AIdF-1 did not affect the proliferation of NBT-II cells, whereas the proliferation of NBT-II/ FGFR-1 cells was inhibited by FGF-1, FGF-2 or AIdF-2. Therefore, the activation of MAP kinase and PI3-K downstream of FGFR-1 or FGFR-2b activation/dimerization did not seem to be sufficient for programming or not the cell cycle entry in S phase, since AIdF-1 activated both pathways at a similar level to that observed on AIdF-2 treatment but failed to affect cell proliferation. These data support previous reports showing that FGF-2 mutants could activate these pathways and cell differentiation without affecting cell proliferation (Kudla et al., 1998; Soulet et al., 2001) . Several authors suggest that signaling events in addition to the FGF's activation of FGFR are necessary to mediate cell responses. It has been proposed that nuclear translocation followed by casein kinase II phosphorylation would be required for Gl-S transition (Soulet et al., 2001) . Although it is not well known how heparin-binding growth factors such as FGF-1 or FGF-2 could enter the nucleus, it is unlikely that it would involve trafficking of HSPGs (Wiedlocha et al., 1994) since anti-idiotypic antibodies do not bind these membrane components. Alternatively, Wiedlocha et al. (1994) proposed a dual mode of signal transduction by externally added FGF-1 involving the stimulation of tyrosine kinase activity of the receptors and nuclear translocation of FGF-1, possibly via the high-affinity receptors (Quarto and Amalric, 1994) . However, this hypothetical transduction mechanism has always been related to the mitogenic activity of FGF-1 or FGF-2 and not to the inhibition of proliferation as shown for NBT-II/FGFR-1 cells. The inhibition of cell proliferation by FGF-2 is not novel and it has already been reported that FGF-2 could inhibit the proliferation of a wide variety of cancer cell lines (Schweigerer et al., 1987) . The use of anti-idiotypic antibodies might help to distinguish between receptordependent and receptor-independent events.
Previously, we showed that tumors derived from FGF-1-transfected NBT-II cells grew faster than tumors obtained with control or FGF-2-transfected cells, irrespective of their angiogenic status (Jouanneau et al., 1997 (Jouanneau et al., , 1999 . Furthermore, NBT-II cellsengineered autocrine for FGF-2 became highly tumorigenic but present the same tumor vascularization (Billottet et al., 2002) . The use of anti-idiotypic antibodies was therefore a powerful tool for deciphering the key events leading to paracrine or autocrine pathways following FGF receptor activation during tumor formation. Despite their ability to promote rabbit corneal angiogenesis, neither AIdF-1 nor AIdF-2 could significantly promote tumor angiogenesis. However, their angiogenic activity in the rabbit corneal model is achieved by a slow-releasing device located in the vicinity of the target endothelial cells. In tumor experiments, the concentration required to elicit tumor angiogenesis might be higher. It is also expected that the half-life of these rabbit IgG should be higher in the rabbit cornea model than in a xenogenic host. Therefore, we cannot exclude that the lack of angiogenesis observed in tumor models might be due to an insufficient delivery to tumor endothelial cells. The role of FGF-1 and FGF-2 in pathological angiogenesis remains controversial. For instance, FGF-2 gene invalidation does not affect the development of retinal vessels nor attenuates pathological choroidal neovascularization following laser injury (Ozaki et al., 1998) . Seghezzi et al. (1998) proposed that the angiogenic Sections of NBT-II or NBTII/FGFR1 tumors challenged with PI-IgG, AIdF-1 or AIdF-2 were paraffin embedded and stained with H&E, or antiVon Willebrandt factor. The number of mitotic figures and Von Willebrandt-positive cells were calculated on at least eight high-power fields on 1500 cells per sample and the ratio of cancer cell islet to the overall surface of tumor tissue was calculated as described in the text. The results are expressed as a percentage and s.e.m.
Direct activation of FGF receptors by soluble agonists B Malavaud et al activity of FGF-2 was mediated by VEGF. In fact, VEGF expression is not upregulated in NBT-II cells either by FGF in vitro or in vivo constitutive expression (Jouanneau et al., 1997; Billottet et al., 2002) or by AIdFl or AId-F2 challenge (data not shown). The fact that AIdF-1 did not modify the tumor growth of NBT-II cells suggests that our previous observation showing that FGF-1-transfected cells led to the formation of fast-growing tumors could not be accounted for by receptor activation alone, and supports the hypothesis that in vivo some functions of FGF-1 are not receptor dependent. In contrast, the in vitro inhibitory activity of AIdF-2 on NBT-II/FGFR-1 cells is well correlated with a reduction in tumor growth, which was unexpected from our previous studies of tumors obtained for FGF-2-transfected NBT-II cells. Aggressiveness of the bladder carcinoma is correlated with the so-called epithelio-mesenchymal transition. Conversely, well-differentiated tumors are formed of carcinoma islets delimited by a basal lamina. Histological analysis of the NBT-II and NBT-II/FGFR-l tumors showed that while AIdF-1 decreased the differentiation of NBT-II tumors, it did not affect that of NBT-II/ FGFR-l tumors. In contrast, the decrease in tumor volume observed after AIdF-2 systemic injections in animals bearing tumors formed with NBT-II/FGFRl cells was parallel to a well-differentiated phenotype highly reminiscent of the histology of highly differentiated human bladder carcinoma which are less aggressive. These experiments demonstrate that the strategy of eliciting anti-idiotypic antibodies of FGF-1 or FGF-2 allows circulating probes specific for each growth factor receptor to be obtained. The molecular mimicry achieved by these agonistic antibodies might constitute a useful tool for understanding the discrepancy observed in the role of FGF receptors in different models of angiogenesis. In the corneal pocket assay, as well as in other models of angiogenesis in which FGFs are supplied as single recombinant molecules, angiogenesis occurs. We demonstrate that the growth factor is not required and that dimerization of FGF receptors in limbal endothelial cells is sufficient to induce corneal angiogenesis. In contrast, when tumors had started to grow, the very same challenge with AIdF-2 was an efficient tool for reducing tumor development through an increase in differentiation but failed to stimulate tumor angiogenesis. These data suggest that FGF receptors are not functional in tumor endothelial cells in contrast to VEGF receptor 2, which is functional in such cells but not in quiescent endothelial cells . Recently, we described a model of endothelial cell culture mimicking the conditions observed in tumor endothelial cells, which highlighted the different ability of endothelial cells to respond to the antiangiogenic pigment epithelialderived factor depending on their FGF-2 or VEGF supply (Hutchings et al., 2002) . Further studies are required to establish the efficacy of such anti-idiotypic antibodies of FGFs as antitumor agents in bladder carcinoma.
Materials and methods

Materials
Tissue culture trays and media were from Poly Labo Paul Block. Chromatography media were from Pharmacia and chemicals from Sigma. FGF-2 and FGF-1 were expressed in a bacterial expression system and iodinated as previously described (Plouet and Gospodarowicz, 1990) . FGFR-1, PI3-K, erk-2 and phosphotyrosine antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), antiphosphorylated PI3-kinase from Upstate Biotechnology (Lake Placid, NY, USA) and antiphosphorylated erk1/2 from Cell Signaling Technology (Beverly, MA, USA). Sodium pyrophosphate, orthovanadate, G418 and antiprotease cocktail were from Sigma-Aldrich (Saint-Quentin-Fallavier, France). Protein ASepharose, heparin-sepharose CL-6B, peroxidase-conjugated goat anti-mouse or rabbit IgG, ECL system and lipofectin were from Amersham Pharmacia Biotech (Rainham, UK). Signaling pathway inhibitors PD98059, LY294002 and wortmannin were purchased from Sigma-Aldrich (Saint-QuentinFallavier, France). AG126 and SB203580 were from Calbiochem-Novabiochem Corp. (La Jolla, CA, USA).
Anti-idiotypic antibodies preparation
Anti-idiotypic antibodies against FGF-1 (AIdF-1) and FGF-2 (AIdF-2) were prepared by monthly injections of 50 mg of neutralizing IgG against FGF-1 or FGF-2, which do not crossreact between them (Plouet and Gospodarowicz, 1990) . Blood samples collected between 4 and 7 months were purified by chromatography on protein A-sepharose and further loaded on a heparin sepharose affinity column in order to remove the putative IgG binding to heparan sulfate proteoglycan (HSPG). Anti-FGF-1-or anti-FGF-2-neutralizing IgG (4 mg), previously dialysed against carbonate buffer 0.2 M pH 8.5, was conjugated to CN-Br sepharose according to the manufacturer's recommendation. A measure of 50 mg of AIdF-1 or AIdF-2 was subjected to these affinity chromatographs and eluted with 0.2 M glycine. The yields of antiidiotypic IgG recovered from anti-FGF-1 and anti-FGF-2 columns were 0.3 and 0.8% of total IgG, respectively, and these values were used to assess the molar concentration (using an average M r of 150 kDa for the IgGs).
Cells
Adrenal cortex-derived capillary endothelial (ACE) cells were cultured in DMEM supplemented with 2 mM glutamine and antibiotics and 10% newborn calf serum (Bugler et al., 1991) . Stock cultures received 1 ng/ml of FGF-2 every other day. NBT-II and NBT-II cells expressing the FGFR1 receptor (NBT-II-FGFR-1) (Savagner et al., 1994; Jouanneau et al., 1997) were cultured in the same medium with 10% fetal calf serum instead of newborn calf serum. Heparan sulfatedeficient CHO cells, constitutively expressing FGFR-1 2 Ig loops or FGFR-1 3 Ig loops (Moscatelli, 1992) , were cultured in DMEM F12 medium supplemented with antibiotics and 10% SVF.
Binding of FGFs and ALdFs
FGF-2 was iodinated with the iodogen procedure (Moscatelli, 1992) with a specific activity of 110 000 c.p.m./ng. Wells containing 2 Â l0 5 serum-starved CHO cells transfected with FGFR-1 containing two Ig loop-coding sequences (binding FGF-1 and FGF-2 with the same affinity) or FGFR-1 containing three Ig loop-coding sequences (binding FGF-1 with an affinity 100-fold lower than FGF-2) (Moscatelli, 1992) were rinsed with cold DMEM medium supplemented with 0.2% gelatin and 20 mM HEPES pH 7.3. These cells were incubated at 41C for 2 h with 2 ng/ml iodinated FGF-2 in the absence or presence of unlabeled FGF-2 or AIdF-2. Cells were then rinsed in the same medium and further lysed in RIPA buffer. The radioactivity was counted in a Packard gamma counter.
Phosphorylation assays
Subconfluent ACE or NBT-II cells were growth-arrested by overnight exposure to 1% FCS supplemented medium. The cells were then rinsed with serum-free medium containing 1 mM sodium pyrophosphate and orthovanadate, and kept at 371C for 10 min. They were then challenged with 1 nM FGF-1 or FGF-2 or 10 nM AIdF-1 or AIdF-2 for various periods of time. In some experiments, 10 mM of PD98059 or wortmannin was added together with the factors. The cell monolayer was then rinsed with cold PBS supplemented with 5 mg/ml of antiprotease cocktail and lysed in RIPA buffer. Lysates (10 7 cells) were incubated for 2 h with 2 mg/ml of either anti-FGFRl or anti-PI3-K rabbit-specific antibodies. The immune complexes were further adsorbed on protein A-sepharose at 41C overnight, washed five times with lysis buffer and solubilized in SDS-PAGE sample buffer. An aliquot of the total lysate corresponding to 10 6 cells was run for MAP kinase detection. The samples were run on 10% acrylamide SDS-PAGE in reducing conditions, transferred to nitrocellulose membrane and revealed with either antiphosphotyrosine or anti-phospho-erkl/2 antibodies. After washing, membranes were revealed by the ECL detection system. Blots were stripped and further reprobed with either anti-PI3-K-or anti-erk-2-specific antibodies. Quantification of the signals was performed with the Image QuaNT software version 4.2a (Molecular Dynamics, Sunnyvale, CA, USA).
Cell proliferation assay
ACE or NBT-II cells were seeded at 5000 cells per well in 12-well cluster plates. The modulators were added every other day. After 5 days, the cells were trypsinized and counted in a Coulter counter. Experiments were performed in the presence or absence of 10 mM of either PD98059, AG126, SB203580, LY294002 inhibitors or 50 nM of wortmannin.
NBT-II scattering assay
The ability of AIdF-1 and AIdF-2 to induce epitheliomesenchymal transition of NBT-II or NBT-II-FGFR-1 cells was assessed by a scattering assay (Savagner et al., 1994) . Cells (5 Â 10 4 ) were seeded in 24 multiwell plates in standard medium in the presence or absence of the anti-idiotypes and control FGF-1 and FGF-2. In parallel, experiments were performed with 10 mM of either PD98059, AG126, SB203580, LY294002 inhibitors or 50 nM of wortmannin, added 2 h prior to modulator addition. Cells were incubated for 3 days; their morphology was observed by light microscopy.
Neovascularization assay
Corneal pocket assays were processed on female New Zealand rabbits as already described . Slow-releasing implants of Hydrogel (2 Â 1 mm 2 ) were rehydrated with 2 ml PBS containing 50 mg of bovine serum albumin, and supplemented or not with 4 pmol of FGF-1, FGF-2, AIdF-1, AIdF-2 or preimmune immunoglobulin (PI-IgG). These implants were inserted into the corneal stroma 2 mm away from the limbus. The neovascularization was assessed on day 12 by direct examination with a slit lamp and scored according to a 4 grade scale. The score represented the mean of the neovascularized area in each condition. The Mann-Whitney test was used for comparison between the different treatments. A P-value of less than 0.05 was considered significant.
Tumors in nude mice and immunohistochemistry
NBT-II cells (3.5 Â 10 6 ) suspended in 500 ml DMEM medium were injected subcutaneously in the flank of 30 female 6-weekold nude mice. Animals were randomly allocated at day 4 into three groups and subsequently given intraperitoneal injections of either PI-IgG preimmune rabbit antibodies or rabbit AIdF-1 or AIdF-2 twice weekly (500 mg in 200 ml of PBS). The largest (L) and smallest (l) dimensions of tumors were measured with a caliper and the volume calculated by the formula L Â l 2 Â 0.52. At day 60, animals were killed by carbon dioxide inhalation and tumors were removed. All specimens were presented blind to the experimenter for the histological studies. Tumor tissue fragments were fixed in formaldehyde/acetic acid/ethanol, paraffin-embedded and stained with HemalunMeyer. The surface ratio of tumor epithelium (cancer) to stroma was assessed by image analysis (C/S ratio). The mitotic index was assessed at high magnification ( Â 400) and corresponded to the number of dividing cells among 1000 cells randomly chosen. For tumor neovascularization studies, cryosections were immunostained with anti-Factor VIII rabbit polyclonal antibodies (DAKO) in the first step, anti-rabbit IgG goat polyclonal biotinylated antibodies in the second step, and endothelial cells were red immunostained with HRP detection. Two high-magnification ( Â 400) digital pictures of each section were taken at random locations. Pictures were processed with Adobe Photoshop software in order to separate the red signal of Factor-VIII-positive endothelial cells from the blue background of epithelial cells. A standardized grid was then applied to the picture and the microvascular density was estimated as the number of cells crossed by any immunostained signal, relative to the total number of cells in the grid (1500 cells).
